KOD Stock Forecast & Price Target

Kodiak Sciences is viewed positively because its ABC platform now appears to combine rapid, unconjugated efficacy with conjugated durability, addressing the major clinical weakness that hurt the original tarcocimab program in GLEAM, GLIMMER, and DAZZLE. The reformulated Zenkuda and KSI-501 programs have since shown phase 3 validation, including BCVA non-inferiority to aflibercept and 54% of wet AMD patients reaching 6-month dosing, while tarcocimab’s 19.6-day ocular half-life compares favorably with faricimab’s 7.5 days. With a three-indication BLA submission planned for 4Q26 across wet AMD, DR, and RVO, plus upcoming KSI-101 readouts in December 2026 and 2Q27, the company has multiple catalysts that could support broader commercialization and value creation.

Kodiak Sciences is a developmental-stage biopharmaceutical company whose value depends heavily on unproven retinal assets, so clinical or commercial setbacks in tarcocimab, KSI-501, or KSI-101 could quickly undermine the investment case. Its own valuation framework assumes meaningful 2036 EPS and cash flows discounted back to December 2026, which highlights how far-dated and execution-dependent the thesis is rather than grounded in current operating strength. The company also faces explicit financing risk, as the cited analysis flags the possibility of failing to secure capital resources while still needing to fund ongoing development and commercialization.